ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 130% and 18.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -23.81% and 5%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 2.78% and 104.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...
Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022...
Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of...
In vitro and cell-based assays suggest narazaciclib’s inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6...
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Conference call and live webcast at 4:30 p.m. ET today...
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.